Immunomedics Inc: Samuel Isaly’s Orbimed Advisors Llc Opened Position

February 14, 2018 - By Louis Casey

Investors sentiment increased to 1.65 in Q3 2017. Its up 0.24, from 1.41 in 2017Q2. It increased, as 16 investors sold Immunomedics, Inc. shares while 36 reduced holdings. 38 funds opened positions while 48 raised stakes. 111.69 million shares or 33.14% more from 83.89 million shares in 2017Q2 were reported.

Orbimed Advisors Llc reported SC 13G/A form with the SEC for Immunomedics Inc. Access it here: 000117266118000522. As reported by Samuel Isaly’s Orbimed Advisors Llc, the filler owns 2.26% or 5,019,776 shares of the Health Care–company.

Immunomedics Inc stake is new for [reportingPerson]. Date of activity: December 31, 2017. This shows Samuel Isaly’s Orbimed Advisors Llc’s positive view for Immunomedics Inc. For a hedge fund managing $6.70 billion in assets and having 72+ experts this is interesting position.

The hedge fund is investor in the Health Care sector. In the manager’s last 13-F, we saw 12% of Samuel Isaly’s Orbimed Advisors Llc’s portfolio is in the sector.

Immunomedics Inc Institutional Sentiment

Filings show 77 investors own Immunomedics Inc. The ownership in Q3 2015 is high, at Infinity of the outstanding shares. This is increased by 10198511. 50388046 were owned by these investors. 13 funds opened new Immunomedics Inc stakes, 26 increased positions. There were 19 that closed positions and 23 reduced them.

Markston International Llc is an investor bullish on Immunomedics Inc, owning 300 shares as of Q3 2015 for less than 0.01% of its portfolio. Krasney Financial Llc owns 44675 shares or 0.02% of its portfolio. GA J-P Turner & Company Capital Mnagement Llc have 0.14% of its portfolio for 4286900 shares. Further, Orbimed Advisors Llc reported stake worth 0.06% of its portfolio. The CA Longwood Capital Partners Llc owns 1711067 shares. Immunomedics Inc is 1.70% of its portfolio.

Business Profile

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.

The stock increased 2.84% or $0.43 during the last trading session, reaching $15.56. About 2.97M shares traded. Immunomedics, Inc. (NASDAQ:IMMU) has risen 76.26% since February 14, 2017 and is uptrending. It has outperformed by 59.56% the S&P500.

Immunomedics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of monoclonal antibody products for the targeted treatment of cancer, autoimmune disorders, and other diseases. The company has market cap of $2.58 billion. The firm engages in developing antibody-drug conjugate products comprising IMMU-132, an ADC that contains SN-38, which is in Phase II trials used for the treatment of patients with metastatic triple-negative breast cancer, and small-cell and non-small-cell lung cancers; IMMU-130, an anti-CEACAN5-SN-38 ADC that is in Phase II trials for the treatment of solid tumors and metastatic colorectal cancer; and IMMU-140 that targets HLA-DR for the potential treatment of liquid cancers. It currently has negative earnings. It also develops products for the treatment of cancer and autoimmune diseases, including epratuzumab, anti-CD22 antibody; veltuzumab, anti-CD20 antibody; milatuzumab, anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody.

Immunomedics, Inc. (NASDAQ:IMMU) Ratings Coverage

Among 3 analysts covering Immunomedics (NASDAQ:IMMU), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Immunomedics has $16 highest and $1.50 lowest target. $15.50’s average target is -0.39% below currents $15.56 stock price. Immunomedics had 15 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, December 6 by Jefferies. The stock of Immunomedics, Inc. (NASDAQ:IMMU) has “Buy” rating given on Monday, July 24 by Cowen & Co. On Thursday, August 17 the stock rating was maintained by Jefferies with “Buy”. Cowen & Co maintained the shares of IMMU in report on Wednesday, December 6 with “Buy” rating. The firm has “Buy” rating given on Friday, June 9 by Jefferies. The rating was maintained by Cowen & Co on Wednesday, August 16 with “Buy”. Jefferies upgraded it to “Buy” rating and $5 target in Friday, May 6 report. Wells Fargo downgraded Immunomedics, Inc. (NASDAQ:IMMU) on Friday, December 4 to “Market Perform” rating. The firm has “Buy” rating by Jefferies given on Monday, October 9. As per Tuesday, March 15, the company rating was maintained by Jefferies.